Evidence map›Paper›PMID 39179734›Full record

ArticleEndocrine2025

The effect of dulaglutide on glycated hemoglobin is associated with PNPLA3 Ι148Μ gene polymorphism in patients with type 2 diabetes mellitus.

Stylianos Gavriilidis, Rozalia Andrianopoulou, Charikleia Ntenti, Anna Sarakapina, Christina Trakatelli, Stergios A Polyzos, Antonis Goulas

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. PNPLA3 I148M Interacts With Environmental Triggers to Cause Human Disease.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Stylianos GavriilidisFirst Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Rozalia AndrianopoulouFirst Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Charikleia NtentiFirst Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Anna SarakapinaThird Department of Internal Medicine, School of Medicine, Aristotle University of Thessaloniki, Papageorgiou Hospital, Thessaloniki, Greece.
Christina TrakatelliThird Department of Internal Medicine, School of Medicine, Aristotle University of Thessaloniki, Papageorgiou Hospital, Thessaloniki, Greece.
Stergios A PolyzosFirst Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Antonis GoulasFirst Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. agoulas@auth.gr.ORCID 0000-0002-8844-5631

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe evaluation of the effect of dulaglutide on glycated hemoglobin (HbA1c) and non-invasive indices of hepatic steatosis among different genotypes of the PNPLA3 I148M (rs738409) and CETP Taq1B (rs708272) polymorphisms in patients with type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD).

methodsRelevant data from patients with inadequately controlled T2DM, also displaying NAFLD, administered 1.5 mg dulaglutide weekly for 6 months were retrospectively retrieved. The non-invasive indices, fatty liver index (FLI) and hepatic steatosis index (HSI), were calculated. Genotyping for rs738409 and rs708272 were performed with polymerase chain reaction.

resultsData from 80 patients (39 females), aged 64.4 ± 9.5 years and displaying a baseline BMI of 34.5 ± 5.8 kg/m

conclusionsrs738409, but not rs708272, was associated with the effect of dulaglutide on HbA1c, but not on presumed hepatic steatosis or other relevant parameters. Sex-specific effects were also noticed.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsImmunoglobulin Fc FragmentsLipaseMembrane ProteinsRecombinant Fusion ProteinsAcyltransferasesAgedFemaleGenotypeHumansMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseAcyltransferasesdulaglutideGlucagon-Like PeptidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsImmunoglobulin Fc FragmentsLipaseMembrane ProteinsPhospholipases A2, Calcium-IndependentPNPLA3 protein, humanRecombinant Fusion ProteinsCholesteryl ester transfer proteinDulaglutideGlucagon-like peptide-1 receptor agonistMetabolic dysfunction associated fatty liver diseaseNonalcoholic fatty liver diseasePatatin-like phospholipase domain-containing 3

Identifiers

PMID39179734

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.